IL-6 Neutralizing Antibody CDR Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for conditions mediated by IL-6, such as rheumatoid arthritis and systemic lupus erythematosus, have limitations in effectively neutralizing IL-6 activity, leading to incomplete disease control and potential side effects.
Innovation Solution
Development of a high-affinity neutralizing antibody specific for human IL-6, comprising specific CDR sequences in its heavy and light chains, which can inhibit IL-6 activity by blocking its binding to the gp130 receptor, thereby reducing inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for IL-6 mediated diseases are used, then treatment can be provided, but IL-6 activity is not effectively neutralized leading to incomplete disease control
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure to achieve high affinity binding to IL-6. The antibody molecules are engineered with specific complementarity determining regions (CDRs) that optimize binding parameters, resulting in effective neutralization of IL-6 activity and improved disease control in conditions like rheumatoid arthritis and systemic lupus erythematosus.
2Reliability
If current therapies are used, then treatment is provided, but side effects occur due to insufficient specific neutralization
Solution Approach 1:
The patent applies local quality by designing antibodies with highly specific local binding characteristics to IL-6. The antibody molecules are engineered with precise CDR sequences that target specific epitopes on IL-6, enabling localized and specific neutralization of the cytokine's harmful effects while preserving other immune functions, thereby reducing therapy side effects.
3Reliability
If high-affinity neutralizing antibody is developed, then IL-6 activity is effectively blocked, but manufacturing complexity increases
Solution Approach 1:
The patent applies copying by using recombinant DNA technology to produce identical copies of the high-affinity antibody molecule. The antibody sequences are cloned into expression vectors and produced in mammalian cell lines, ensuring consistent high-affinity binding while streamlining manufacturing through standardized bioprocessing methods.
Data Source
AI summary
The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.